Long product cycles, complex revenue recognition, and an operating model built around scientific milestones, not quarters.
Life sciences companies operate on cash burn timelines tied to scientific milestones, with revenue models that range from contract milestones to royalties to product sales. ASC 606 in this space is a discipline of its own. Sponsor and investor reporting needs to translate scientific progress into financial milestones a board can act on — without losing sight of the runway math that defines every quarter.
Sub-Sectors We Work In
ASC 606 for milestones, royalties, collaborations, and multi-element arrangements — with the memos and the system support to back it up.
13-week cash, runway models tied to scientific milestones, and the scenario analyses that inform every funding decision.
Project-level cost capture, capitalization vs expense, grant tracking, and the program-level economics investors expect.
Sponsor reporting, IPO readiness, sell-side prep, and the financial story that turns scientific progress into investor confidence.
Interim CFO and Controller seats, audit readiness, and the close discipline most early-stage life sciences companies need by Series B.
Board packs, investor updates, lender packs, and the KPI rhythm that keeps the management team and board aligned through clinical and commercial milestones.
Runway models, milestone-based forecasts, and the investor reporting cadence a life sciences company needs.
ASC 606 for milestones and collaborations. Grant accounting. IPO readiness. Audit support.
Unifying clinical trial, lab operations, and financial data into investor-grade dashboards.
Document intelligence on collaboration agreements and grant contracts, AI agents for trial site reporting.
Tell us where the friction lives in your life sciences portfolio company and we’ll scope a solution that fits the way the business actually runs.
CONNECT WITH US